Free Trial

Minerva Neurosciences (NERV) Competitors

Minerva Neurosciences logo
$1.76 -0.04 (-1.98%)
Closing price 04:00 PM Eastern
Extended Trading
$1.78 +0.02 (+1.14%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NERV vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXW

Should you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry.

Minerva Neurosciences vs. Its Competitors

180 Life Sciences (NASDAQ:ATNFW) and Minerva Neurosciences (NASDAQ:NERV) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
180 Life SciencesN/AN/AN/AN/AN/A
Minerva NeurosciencesN/AN/A$1.44M$0.822.15

180 Life Sciences' return on equity of 0.00% beat Minerva Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
180 Life SciencesN/A N/A N/A
Minerva Neurosciences N/A -20.68%15.73%

34.6% of Minerva Neurosciences shares are owned by institutional investors. 8.6% of Minerva Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Minerva Neurosciences has a consensus price target of $5.00, suggesting a potential upside of 184.09%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Minerva Neurosciences is more favorable than 180 Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
180 Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Minerva Neurosciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, 180 Life Sciences' average media sentiment score of 0.00 equaled Minerva Neurosciences'average media sentiment score.

Company Overall Sentiment
180 Life Sciences Neutral
Minerva Neurosciences Neutral

Summary

Minerva Neurosciences beats 180 Life Sciences on 5 of the 6 factors compared between the two stocks.

Get Minerva Neurosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NERV vs. The Competition

MetricMinerva NeurosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$12.30M$2.41B$5.45B$9.68B
Dividend YieldN/A1.78%3.99%4.14%
P/E Ratio2.1520.1630.1125.01
Price / SalesN/A444.85379.5578.79
Price / Cash8.64165.0335.9458.58
Price / Book-0.484.128.135.68
Net Income$1.44M$31.61M$3.26B$265.68M
7 Day Performance-8.57%0.46%1.15%2.51%
1 Month Performance7.98%2.42%2.82%1.88%
1 Year Performance-40.54%4.44%28.41%24.00%

Minerva Neurosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NERV
Minerva Neurosciences
2.7599 of 5 stars
$1.76
-2.0%
$5.00
+184.1%
-37.9%$12.30MN/A2.159
ATNFW
180 Life Sciences
N/A$0.01
-12.4%
N/A-7.4%$0.00N/A0.007
LBPSW
4D pharma
N/AN/AN/AN/A$0.00$522K0.00N/A
AEHAW
Aesther Healthcare Acquisition
N/A$0.01
+84.9%
N/A-75.6%$0.00N/A0.002Gap Down
AIMDW
Ainos
N/A$0.12
flat
N/AN/A$0.00$106.21K0.0040Gap Up
ALVOW
Alvotech
N/A$1.60
-17.5%
N/A-52.1%$0.00$585.60M0.004Gap Down
ARAV
ARAVIVE
N/A$0.04
flat
N/AN/A$0.00$9.14M0.0020High Trading Volume
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.05
+2.9%
N/A+2.0%$0.00N/A0.0015Gap Up
BFRIW
Biofrontera
N/A$0.15
+2.5%
N/AN/A$0.00$38.00M0.0070Gap Down
BTMDW
biote
N/A$0.02
+19.3%
N/A-96.2%$0.00$199.38M0.00N/AGap Up
BCTXW
BriaCell Therapeutics
N/A$0.04
+9.4%
N/A-85.5%$0.00N/A0.008Negative News
Gap Up

Related Companies and Tools


This page (NASDAQ:NERV) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners